fda warning letters glp-1 compounders september 2025 news 8, 2025: launches an import alert listing safe manufacturers – Partnership for Safe Medicines U.S. FDA | FDA is

Diabetes Care 34, 604606

Short bowel patients treated for two years with glucagon-like peptide 2: Effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function

[DOI] [PubMed] [Google Scholar] 86.Alferink L.J.M., Erler N.S., de Knegt R.J., et al

Drug development companies conducting rapid clinical trials are anticipated to significantly accelerate the market revenue expansion of the GLP-1 receptor market over the forecast period

Research published in a 2025 narrative review found that GLP-1 medications can lead to muscle loss, micronutrient deficiencies, and digestive disruptions if nutritional needs aren't actively managed